Expertise in
3
conditions

Marie-pierre P. Sunyach

28, Rue Laennec, 
Lyon, FR 
Expertise in
3
conditions
28, Rue Laennec, 
Lyon, FR 

Overview

Marie-pierre Sunyach practices practicing medicine in Lyon, France.

Sunyach is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Adult Soft Tissue Sarcoma, Pineocytoma, Desmoid Tumor, and Angiosarcoma.

They are actively involved in clinical research, co-authoring 63 peer reviewed articles and participating in 8 clinical trials.

Locations

28, Rue Laennec, Lyon, 69008, France
Other Locations
Leon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost Guided by Magnetic Resonance Spectroscopic Imaging
Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost Guided by Magnetic Resonance Spectroscopic Imaging
Enrollment Status: Terminated
Publish Date: April 14, 2026
Intervention Type: Radiation
Study Phase: Phase 3
A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Combination product
Study Drug: Atezolizumab
Study Phase: Phase 2
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation
Study Drugs: Olaparib, Temozolomide (TMZ)
Study Phase: Phase 1/Phase 2
Phase II Study to Assess Preoperative Hypofractionated Stereotactic Radiotherapy of Brain Metastases
Phase II Study to Assess Preoperative Hypofractionated Stereotactic Radiotherapy of Brain Metastases
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Procedure
Study Phase: Phase 2
Randomized Controlled Trial Evaluating the Efficacy of an Adapted Physical Activity Program Using a Connected Device With Activity Trackers and a Therapeutic Education Program Among Women With Localized Breast Cancer
Randomized Controlled Trial Evaluating the Efficacy of an Adapted Physical Activity Program Using a Connected Device With Activity Trackers and a Therapeutic Education Program Among Women With Localized Breast Cancer
Enrollment Status: Completed
Publish Date: March 22, 2023
Intervention Type: Device, Behavioral
Study Phase: Not Applicable
Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative
Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative
Enrollment Status: Terminated
Publish Date: March 25, 2020
Intervention Type: Radiation
Study Phase: Not Applicable
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
Enrollment Status: Terminated
Publish Date: May 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Randomised Multicentric Phase III Study Comparing Observation Versus Post-surgery Radiotherapy After Complete Exeresis With Margins Greater Than or Equal to 1 cm in Soft Tissues Members Sarcoma.
Randomised Multicentric Phase III Study Comparing Observation Versus Post-surgery Radiotherapy After Complete Exeresis With Margins Greater Than or Equal to 1 cm in Soft Tissues Members Sarcoma.
Enrollment Status: Terminated
Publish Date: August 22, 2018
Intervention Type: Other, Radiation
Study Phase: Phase 3
View 7 Less Clinical Trials

63 Total Publications

Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.
Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 17, 2026

Frequently Asked Questions about Marie-pierre P. Sunyach

Is Marie-pierre P. Sunyach a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Marie-pierre P. Sunyach is classified as an Distinguished expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marie-pierre P. Sunyach participate in research or clinical trials?

Yes. Marie-pierre P. Sunyach has published 63 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Marie-pierre P. Sunyach's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sunyach's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile